Acrivon Historical Financial Ratios
| ACRV Stock | 7.16 0.61 9.31% |
Acrivon Therapeutics, is presently reporting on over 86 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.94 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Acrivon Therapeutics, financial condition quickly.
Acrivon |
About Acrivon Financial Ratios Analysis
Acrivon Therapeutics,Financial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Acrivon Therapeutics, investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Acrivon financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Acrivon Therapeutics, history.
Acrivon Therapeutics, Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Acrivon Therapeutics,'s fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Acrivon Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Acrivon Therapeutics,'s Price Book Value Ratio is fairly stable compared to the past year. Ebt Per Ebit is likely to climb to 1.24 in 2024, whereas Operating Cash Flow Per Share is likely to drop (2.03) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 34.46 | 19.61 | 9.75 | 13.32 | Net Debt To EBITDA | 6.1 | 0.82 | 0.52 | 0.5 |
Acrivon Therapeutics, fundamentals Correlations
Click cells to compare fundamentals
Acrivon Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.